Business
Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update
Plans to initiate three clinical studies in chronic cough indications for later this year remain on track Data from Phase 2 CANAL trial of chronic cough in
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Plans to initiate three clinical studies in chronic cough indications for later this year remain on track\nData from Phase 2 CANAL trial of chronic cough in patients with idiopathic pulmonary fibrosis published in NEJM Evidence\nManagement to host a conference call and webcast today at 4:30 p.m. EDT\nNEW HAVEN, Conn., Aug. 10, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced financial results for the quarter ended June 30, 2023, as well as provided business updates.\n\n \n \n \n \n \n \n\n \nPlans to initiate three clinical studies in chronic cough indications for later this year remain on track\"Our development plans remain on track in our chronic cough programs and we expect to initiate clinical trials in both chronic cough in IPF and refractory chronic cough in the second half of this year,\" said Jennifer Good, President and CEO of Trevi Therapeutics. \"We are currently in the regulatory submission phase in various countries to support trial initiations. We were encouraged by the high degree of scientific and clinical interest at the medical meetings held this quarter surrounding our data generated in chronic cough in IPF and the potential of Haduvio's mechanism of action to broadly treat chronic cough.\"\nKey Business Updates\nPreparation for the initiation of three chronic cough trials (Phase 2b dose ranging trial for treatment of chronic cough in patients with IPF, Phase 1b trial to evaluate respiratory physiology in patients with IPF, and Phase 2a trial in refractory chronic cough (RCC)) continues to advance as we work through the regulatory submission process in multiple countries. All trials are expected to be initiated in the second half of this year.Announced publication of positive data from the Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in IPF in NEJM Evidence.Working on securing supply of the comparator drug IV butorphanol to complete the final part of the Human Abuse Potential study. There was an identified shortage of IV butorphanol due to a single supplier and recent tornado damage to their manufacturing p...